Molecular characterization of adenocarcinoma of the cervix

Gynecologic Oncology

Volumn 64, Issue 2, 1997, Pages 242-251

  Parker, M F ^a   Arroyo, G F ^b   Geradts, J ^c   Sabichi, A L ^b   Park, R C ^a   Taylor, R R ^a   Birrer, M J ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER STAGING; CLINICAL ARTICLE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN SYNTHESIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; UTERINE CERVIX CARCINOMA;

EID: 0031080916     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.4580     Document Type: Article

References (39)

1. 1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1996. CA Cancer J Clin 46:5-27, 1996
2. 2. Hatch KD: Cervical Cancer, in Berek JS, Hacker NF (eds): Practical Gynecologic Oncology, 2nd ed. Baltimore, MD, Williams & Wilkins, 1994
3. 3. Devesa SS, Joung JL Jr, Brinton LA, Fraumeni JF: Recent trends in cervix uteri cancer. Cancer 64:2184-2190, 1989
4. 4. Wittinghofer F, Krengel U, John J, Kabsch W, Pai EF: Three-Dimensional Structure of p21 in the Active Conformation and Analysis of Oncogenic Mutants, in Brugge J, Curran T, Harlow E, McCormick F (eds): Origins of Human Cancer: A Comprehensive Review. Plainview, NY, Cold Spring Harbor Laboratory Press, 1991
5. 5. Bos JL: Ras oncogenes in human cancer: A review. Cancer Res 49:4682-4689, 1989
6. 6. Hollstein M, Sidransky D, Vogelstein B, Harris C: p53 mutations in human cancer. Science 253:49-53, 1991
7. ink4 expression in primary lung cancers and cell lines. Cancer Res 55:505-509, 1995
8. 8. Goodrich DW: Signaling the cell cycle. Cancer Bull 47:163-170, 1995
9. 9. Hunter T, Pines J: Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 79:573-582, 1994
10. 10. Zhang S, Klein-Szanto AJP, Sauter ER, Shafaenko M, Mitsunaga S, Nobori T, Carson D, Ridge JA, Goodrow TL: Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 54:5050-5053, 1994
11. 11. Wadayama B, Toguchida J, Shimizu T, Ishizaki K, Sasaki MS, Kotoura Y, Yamamuro T: Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res 54:3042-3048, 1994
12. 12. Lancaster WD: Viral role in cervical and liver cancer. Cancer 70:1794-1798, 1992
13. 13. Gissman L: Human papillomaviruses and genital cancer. Semin Cancer Biol 3:253-261, 1992
14. 14. Leminen A, Paavonen J, Vesterinen E, Wahlstrom T, Rantala I, Lehtinen M: Human papillomavirus types 16 and 18 in adenocarcinoma of the uterine cervix. Am J Clin Pathol 95:647-652, 1991
15. 15. Woodworth CD, Doniger J, DiPaolo JA: Immortalization of human foreskin keratinocytes by various human papillomavirus DNAs corresponds to their association with cervical carcinoma. J Virol 63:159-164, 1989
16. 16. DiPaolo JA, Woodworth CD, Popescu NC, Notario V, Doniger J: Induction of human cervical squamous cell carcinoma by sequential transfection with human papillomavirus 16 DNA and viral Harvey ras. Oncogene 4:395-399, 1989
17. 17. Werness DA, Levine AJ, Howley PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76-79, 1990
18. 18. Wright DK, Manos MM: Sample Preparation from Paraffin-Embedded Tissues, in Innis MA, Gelfand DH, Sninsky JJ, White TJ, (eds): PCR Protocols: A Guide to Methods and Applications. San Diego, CA, Academic Press, 1990
19. 19. Mitsudomi T, Viallet J, Mulshine JL, Linnoila RI, Minna JD, Gazdar AF: Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 6:1353-1362, 1991
20. 20. Teneriello MG, Ebina M, Linnoila RI, Henry M, Nash JD, Park RC, Birrer MJ: p53 and K-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 53:3103-3108, 1993
21. 21. Geradts J, Hu SX, Lincoln CE, Benedict DWF, Xu HJ: Aberrant Rb gene expression in routinely processed, archival tumor tissues determined by three different anti-Rb antibodies. Int J Cancer 58:161-167, 1994
22. INK4A in archival solid tumors: Correlation with retinoblastoma protein expression. Cancer Res 55:6006-6011, 1995
23. 23. Jiko K, Tsuda H, Sato S, Hirohashi S. Pathogenetic significance of p53 and c-Ki-ras gene mutations and human papillomavirus DNA integration in adenocarcinoma of the uterine cervix and uterine isthmus. Int J Cancer 59:601-606, 1994
24. 24. Koulos JP, Wright TC, Mitchell MF, Silva E, Atkinson EN, Richart RM: Relationships between c-Ki-ras mutations, HPV types, and prognostic indicators in invasive endocervical adenocarcinomas. Gynecol Oncol 48:364-369, 1993
25. 25. Duggan BD, Felix JC, Muderspach LI, Tsao JL, Shibata DK: Early mutational activation of the c-Ki-ras oncogene in endometrial carcinoma. Cancer Res 54:1604-1607, 1994
26. 26. Sasaki H, Nishii H, Takahashi H, Tada A, Furusato M, Terashima Y, Siegal GP, Parker SL, Kohler MF, Berchuck A, Boyd J: Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res 53:1906-1910, 1993
27. 27. Ignar-Trowbridge D, Risinger JI, Dent GA, Kohler M, Berchuck A, McLachlan JA, Boyd J: Mutations of the Ki-ras oncogene in endometrial carcinoma. Am J Obstet Gynecol 167:227-232, 1992
28. 28. Tsuda H, Hirohashi S: Frequent occurrence of p53 gene mutations in uterine cancers at advanced clinical stage and with aggressive histologic phenotypes. Jpn J Cancer Res 83:1184-1191, 1992
29. 29. Kohler MF, Berchuck A, Davidoff AM, Humphrey PA, Dodge RK, Iglehart JD, Soper JT, Clarke-Pearson DL, Bast RC Jr, Marks JR: Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 52:1622-1627, 1992
30. 30. Busby-Earle RMC, Steel CM, Williams ARW, Cohen B, Bird CC: p53 mutations in cervical carcinogenesis - Low frequency and lack of correlation with human papillomavirus status. Br J Cancer 69:732-737, 1994
31. 31. Holm R, Skomedal H, Heiland A, Kristensen G, Borresen AL, Nesland JM: Immunohistochemical analysis of p53 protein overexpression in normal, premalignant, and malignant tissues of the cervix uteri. J Pathol 169:21-26, 1993
32. 32. Inoue M, Okayama A, Fujita M, Enomoto T, Sakata M, Tanizawa O, Ueshima H: Clinicopathological characteristics of p53 overexpression in endometrial cancers. Int J Cancer 58:14-19, 1994
33. 33. Nielsen AL, Nyholm HCJ: p53 protein and c-erbB-2 protein (p185) expression in endometrial adenocarcinoma of endometrioid type - An immunohistochemical examination in paraffin sections. Am J Clin Pathol 102:76-79, 1994
34. 34. Enomoto T, Fujita M, Inoue M, Nakazawa-Miyamoto A, Tanizawa O, Nomura T: Alterations of the Rb gene and its association with Ki-ras activation and p53 inactivation in endometrial adenocarcinoma. Mol Carcinogen 8:132-137, 1993
35. 35. Hatta Y, Hirama H, Takeuchi S, Lee E, Pham E, Miller CW, Strohmeyer T, Wilczynski SP, Melmed S, Koeffler HP: Alterations of the p16 (MTS1) gene in testicular, ovarian, and endometrial malignancies. J Urol 154:1954-1957, 1995
36. 36. Peiffer SL, Bartsch D, Whelan AJ, Mutch DG, Herzog TJ, Goodfellow PJ: Low frequency of CDKN2 mutation in endometrial carcinomas. Mol Carcinogen 13:210-212, 1995
37. 37. Das BC, Gopalkrishna V, Das DK, Sharma JK, Singh V, Luthra UK: Human papilloma virus DNA sequences in adenocarcinoma of the uterine cervix in Indian women. Cancer 72:147-253, 1993
38. 38. Samaratunga H, Cox N, Wright RG: Human papilloma virus DNA in glandular lesions of the uterine cervix. J Clin Pathol 46:718-721, 1993
39. 39. Lai CH, Hsueh S, Lin CY, Huang MH, You GB, Chang HC, Pao CC: Human papillomavirus in benign and malignant ovarian and endometrial tissues. Int J Gynecol Pathol 11:210-215, 1992